A team at Yale University has shown that angiophagy, a way the vascular system deals with clots, is far more common and occurs in many more organs than previously suspected. Read More
Northwest Biotherapeutics Inc., of Bethesda, Md., said the data safety monitoring board has made an unblinded review of the safety data for the company’s ongoing international phase III glioblastoma trial with DCVax-L, using activated dendritic cells, and has recommended that the trial continue as planned. Read More
Intrexon Corp., of Germantown, Md., completed the acquisition of Medistem Inc., of San Diego. The $26 million acquisition provides Intrexon with a platform of endometrial regenerative cells derived from menstrual blood for use with integrated synthetic biology platforms to develop cell-based therapies across a range of conditions. Read More
After a three-week respite – giving IPO-weary investment bankers and industry analysts a chance to catch up after the rapid succession of pricings in early February – Aquinox Pharmaceuticals Inc. and Recro Pharma Inc. priced initial public offerings Friday as expected, and both made solid if not stunning debuts despite the mystery biopharma sell-off of late last week. Read More
Newlink Genetics Corp. said Friday its phase III IMPRESS trial of algenpantucel-L in patients with surgically resected pancreatic cancer will continue without modification on the recommendation of the independent data safety monitoring board (DSMB) following the first of two planned interim analyses. Read More
Incyte Corp. could achieve label expansion with the already successful myelofibrosis (MF) drug Jakafi (ruxolitinib) by the end of this year, thanks to a phase III victory in the myeloproliferative neoplasm known as polycythemia vera (PV), which sometimes advances to MF. Read More
LONDON – Galapagos NV is putting its drug discovery services arm on the market to provide funding for the clinical development of its internal pipeline. Read More
Clinical trials for Alzheimer’s disease find themselves with a frustrating conundrum these days. The scientific evidence for what is the root problem of the disease keeps getting better – and clinical trials based on that scientific evidence keeps going nowhere. Read More
LONDON – Verona Pharma plc is riding the wave of investor exuberance for biotech, attracting U.S. and UK institutional investors to take up new shares to the value of £14 million (US$23.4 million). Read More
